financetom
Business
financetom
/
Business
/
AbbVie Unusual Options Activity For April 05
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AbbVie Unusual Options Activity For April 05
Apr 5, 2024 1:47 PM

Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie ( ABBV ).

Looking at options history for AbbVie ( ABBV ) we detected 25 trades.

If we consider the specifics of each trade, it is accurate to state that 32% of the investors opened trades with bullish expectations and 68% with bearish.

From the overall spotted trades, 11 are puts, for a total amount of $593,316 and 14, calls, for a total amount of $795,585.

Predicted Price Range

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $125.0 to $195.0 for AbbVie ( ABBV ) over the last 3 months.

Volume & Open Interest Development

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AbbVie's ( ABBV ) options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AbbVie's ( ABBV ) substantial trades, within a strike price spectrum from $125.0 to $195.0 over the preceding 30 days.

AbbVie Option Volume And Open Interest Over Last 30 Days

Significant Options Trades Detected:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
ABBV CALL TRADE BEARISH 01/17/25 $5.0 $4.8 $4.8 $195.00 $163.2K 1.2K 341
ABBV PUT TRADE BULLISH 01/17/25 $21.35 $21.0 $21.0 $185.00 $128.1K 32 67
ABBV CALL SWEEP BEARISH 04/26/24 $2.28 $2.12 $2.28 $175.00 $91.2K 279 2.2K
ABBV CALL TRADE BEARISH 05/17/24 $5.4 $5.3 $5.3 $170.00 $90.1K 5.6K 292
ABBV PUT TRADE BEARISH 01/17/25 $2.5 $2.28 $2.5 $130.00 $85.0K 1.7K 340

About AbbVie

AbbVie ( ABBV ) is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

In light of the recent options history for AbbVie ( ABBV ), it's now appropriate to focus on the company itself. We aim to explore its current performance.

Where Is AbbVie Standing Right Now?

Currently trading with a volume of 6,634,397, the ABBV's price is up by 1.25%, now at $170.0.

RSI readings suggest the stock is currently may be approaching oversold.

Anticipated earnings release is in 21 days.

What Analysts Are Saying About AbbVie

In the last month, 2 experts released ratings on this stock with an average target price of $192.5.

An analyst from Barclays persists with their Overweight rating on AbbVie ( ABBV ), maintaining a target price of $195.

An analyst from Guggenheim has decided to maintain their Buy rating on AbbVie ( ABBV ), which currently sits at a price target of $190.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for AbbVie ( ABBV ), Benzinga Pro gives you real-time options trades alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Payfare Receives Vendor's SOC 1 Report, Provides Update on Annual Filings
Payfare Receives Vendor's SOC 1 Report, Provides Update on Annual Filings
Jul 2, 2024
06:22 AM EDT, 07/02/2024 (MT Newswires) -- Payfare ( PYFRF ) , an international earned wage access company, over the holiday weekend said that it has received the System and Organization Controls auditor's report from its material vendor. The company's independent auditors require the report to complete their required audit procedures to issue their opinion on the company's annual financial...
Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study
Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study
Jul 2, 2024
July 2 (Reuters) - Cartesian Therapeutics ( RNAC ) said on Tuesday that its experimental autoimmune disorder therapy met the main goal of a mid-stage trial. ...
Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 2, 2024
06:23 AM EDT, 07/02/2024 (MT Newswires) -- A Delaware Superior Court judge rejected an appeal from GSK (GSK) and other drugmakers to overturn a ruling that cleared the way for over 70,000 lawsuits alleging that the heartburn drug Zantac causes cancer, Reuters reported late Monday. Judge Vivian Medinilla resoundingly rejected GSK, Boehringer Ingelheim, Pfizer ( PFE ), and Sanofi's (...
Bombardier Settled New York Bondholder Lawsuit
Bombardier Settled New York Bondholder Lawsuit
Jul 2, 2024
06:16 AM EDT, 07/02/2024 (MT Newswires) -- Bombardier (BBD-A.TO, BBD-B.TO) over the holiday weekend reached an agreement to settle the lawsuit titled Antara Capital Master Fund LP, Corbin ERISA Opportunity Fund Ltd. and Corbin Opportunity Fund, L.P. v. Bombardier Inc., et al. A statement noted the Lawsuit is pending in New York State Supreme Court, Commercial Division New York County...
Copyright 2023-2026 - www.financetom.com All Rights Reserved